Navigation Links
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Date:5/28/2009

MELBOURNE, Australia, May 28 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) announced that it will present preliminary data from its Phase I clinical trial of orally administered CYT997, at the Annual Meeting of the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.

Dr Alessandra Francesconi, one of the clinical investigators for the program, will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8:00 AM to 12:00 PM (US EST), Level 2, West Hall C.

The poster entitled "Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer" details safety, tolerability and preliminary activity findings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma.

Enquiries


    Dr. Gregg Smith                            Mr. Andrew Macdonald
    Director, Drug Development and Operations  Chief Executive Officer
    T: +61 3 9208 4234                         T: +61 3 9208 4232
    gregg.smith@cytopia.com.au                 andrew.macdonald@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cytopia Presentation on VDA CYT997 at AACR Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 Marktech ... of deep ultra violet emitters in the 280 nm ... standard UV emitters which range from 280nm to 405nm. ... and water sanitation as well as curing. Mark Campito, ... line of special interest to manufacturers is that we ...
(Date:9/23/2014)... New spin-out from Cancer ... Innovation Capital and Johnson & Johnson Development Corporation  ... focused on harnessing the potential of circulating tumour ... treatment, today announced it has raised £4m in ... including Cambridge Innovation Capital and Johnson & Johnson ...
(Date:9/22/2014)... , September 22, 2014 ... announced the addition of the "Global Biotechnology ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology ... added to a system to detect and examine ... are generally used in laboratories to prepare, collect, ...
(Date:9/22/2014)... new star-shaped molecule made up of interlocking rings, which is ... , Known as a ,Star of David, molecule, scientists have ... a century and the team,s findings are published in the ... molecular triangles, entwined about each other three times into a ... is 114 atoms in length around the perimeter. The molecular ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3
... N.J., June 27 Wyeth (NYSE: WYE ) ... Executive,Officer, has assumed the additional position of Chairman of ... a previously announced election by the,Company,s Board of Directors, ... in April 2006 when Mr. Poussot was promoted to ...
... and Received over $235 Million, SOUTH SAN FRANCISCO, ... announced today that the company and,GlaxoSmithKline, Inc. (NYSE: ... conclusion on October 27, 2008, as scheduled. Under the,terms ... up to two of the,compounds in the collaboration for ...
... between 30 and 50 million people. In the infected ... distress syndrome (ARDS). This fatal condition is a massive ... severely damaged. ARDS can be induced by various bacterial ... could be toxic gases that are inhaled or gastric ...
Cached Biology Technology:Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 2Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 3Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 4Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration 5New strategies against bird flu 2
(Date:9/23/2014)... of animals and plants. The central problem in pattern ... a reliable manner to give specific spatial patterns of ... formation is a classic paradigm in developmental biology. Cell ... flag, is caused by a gradient of a signalling ... of the morphogen a "blue", "white" or "red" gene ...
(Date:9/23/2014)... SPRINGS, Florida , September 23, 2014 ... for innovative companies in tech sector position for significant investor ... products & services.  Companies in focus today are: NXT-ID, Inc. ... BABA ), Mobileye N.V. (NYSE: MBLY ... Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
(Date:9/22/2014)... GAINESVILLE, Fla. --- Many native species have vanished ... University of Florida scientists have discovered how fossils ... , The key lies in organic materials found ... ancient ecosystems functioned, according to a new study ... the Journal of Herpetology . Pre-human island ...
Breaking Biology News(10 mins):Recreating the stripe patterns found in animals by engineering synthetic gene networks 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7Answer to restoring lost island biodiversity found in fossils 2
... GABLES, FL. -- The key to understanding how future hurricanes ... native coastal forests lurks below the surface, according to a ... the familiar mangroves that line the coasts lie hardwood hammocks ... the soils., University of Miami (UM) Ecologist Donald L. DeAngelis, ...
... of Houston (UH) vision scientist has received a $1.85 ... to investigate whether his techniques are more effective than ... could lead to developing a way to earlier diagnose ... assistant professor of vision science and biomedical engineering, uses ...
... warming and instead reduce fossil-fuel use for the sake of ... from the University of Washington and one from the University ... current issue of the journal Nature (Jan. 26) ... trump the environment as a reason to curb the use ...
Cached Biology News:Living on the edge: An innovative model of mangrove-hammock boundaries in Florida 2Sharper imaging in glaucoma focus of $1.85 million NIH grant 2Sharper imaging in glaucoma focus of $1.85 million NIH grant 3Commentary in Nature: Can economy bear what oil prices have in store? 2Commentary in Nature: Can economy bear what oil prices have in store? 3